Tissue Regenix Group Regulatory News (TRX)

 Tissue Regenix Group plc

('Tissue Regenix' or 'the Group')

Board Changes

Jay LeCoque appointed as Executive Chairman

Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces the following changes to its Board of Directors.

Jay LeCoque will join the Board of Tissue Regenix as Executive Chairman, effective from today. Jay brings extensive experience from his role as Executive Chairman of Source BioScience Limited, Commercial Director of Bioquell PLC, and CEO of Celsis International PLC and Limited. He has over 25 years of senior management experience in the global business development of UK listed and privately held life sciences companies. 

Jonathan Glenn, Chairman, and Trevor Phillips, Non-Executive Director, have both resigned from the Board, effective from today. The Company thanks both Jonathan and Trevor for their dedication and valuable contributions during their time on the Board.

Daniel Lee, CEO of Tissue Regenix, commented: "On behalf of the Board, I would like to thank Jonathan and Trevor for their commitment and support to the Company over the years. They have each made valued contributions to the Group and I wish them all the best in their future endeavours.

"We are pleased to appoint Jay LeCoque as Executive Chairman. His extensive knowledge and experience in the global healthcare and the clinical life sciences sector will contribute greatly to the business as we continue to grow and strengthen earnings to meet our long-term objectives."

Additional disclosures required under Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies

Jay Charles LeCoque, aged 62, has held the following directorships or partnerships in the past five years:

Mr LeCoque and persons closely associated (as defined under MAR) with Mr LeCoque do not currently hold any shares in the Company.

Save as disclosed above, there is no further information to be disclosed in respect of the above appointment pursuant to Rule 17 and Schedule 2 paragraph (g) of the AIM Rules for Companies.

For more information:

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries and wound care.